Opendata, web and dolomites

TAT-CF SIGNED

Novel therapeutic approaches for the treatment of cystic fibrosis based on small molecule transmembrane anion transporters

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "TAT-CF" data sheet

The following table provides information about the project.

Coordinator
UNIVERSIDAD DE BURGOS 

Organization address
address: HOSPITAL DEL REY
city: BURGOS
postcode: 9001
website: www.ubu.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.tat-cf.eu
 Total cost 4˙591˙287 €
 EC max contribution 4˙591˙287 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-PHC-2015-two-stage
 Funding Scheme RIA
 Starting year 2016
 Duration (year-month-day) from 2016-01-01   to  2018-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSIDAD DE BURGOS ES (BURGOS) coordinator 665˙563.00
2    AVIDIN KUTATO, FEJLESZTO ES KERESKEDELMI KFT HU (SZEGED) participant 732˙875.00
3    CONSIGLIO NAZIONALE DELLE RICERCHE IT (ROMA) participant 610˙273.00
4    BIOKERALTY RESEARCH INSTITUTE AIE ES (ARCAUTE ALAVA) participant 591˙875.00
5    BIONEER A/S DK (HOERSHOLM) participant 557˙375.00
6    STEINBEIS INNOVATION GGMBH DE (STUTTGART) participant 523˙953.00
7    AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS ES (MADRID) participant 519˙368.00
8    ISTITUTO GIANNINA GASLINI IT (GENOVA) participant 390˙002.00

Map

 Project objective

This project will develop an innovative therapeutic approach for the treatment of Cystic Fibrosis (CF). This condition originates from the defective function of the CFTR protein, a chloride and bicarbonate permeable transmembrane channel. This project will evaluate small molecules capable of facilitating the transmembrane transport of anions such as chloride and bicarbonate and will thus enable CF treatment by replacing the missing CFTR anion permeation activity. This represents an unexplored path in the treatment of CF and a paradigm shift with respect to current strategies searching for a cure for CF. Instead of focusing on the development of mutation-specific treatments, we plan to develop a therapy applicable to CF patients, regardless of the type of mutation they harbor. Thus, this therapeutic approach overcomes the limitation of current mutation-specific treatments and is applicable to CF patients in general. To achieve this goal we have set up a comprehensive program to validate a research concept and complete the preclinical development of a new lead compound, making it ready for early clinical development. A rmultidisciplinary team of qualified researchers have been assembled to bring to conclusion a truly translational project from the synthesis of new compounds to validation on animal models. Cystic Fibrosis affects more people than any other rare disease. Therefore, it could be said, at least in quantitative terms, that CF qualifies as the main target of the topic. This project aims to complete the preclinical development of novel, innovative drugs based on a radically new concept in Cystic Fibrosis therapies. This result fully addresses the expected impact set out in the work programme of advancing the development of new therapeutic options for patients living with rare diseases as well as contributing to reach the IRDiRC objective to deliver 200 new therapies for rare diseases by 2020.

 Deliverables

List of deliverables.
Lung epithelial cells from F508del patients Documents, reports 2019-07-26 14:38:12
Biophysical and pharmacological characterisation of the anionophores Documents, reports 2019-07-26 14:38:13
Project Website Websites, patent fillings, videos etc. 2019-07-26 14:38:13
Anionophores in F508del and G551D mouse models Documents, reports 2019-07-26 14:38:13
Physiology of normal and cystic fibrosis bronchial epithelium; Imaging assay Documents, reports 2019-07-26 14:38:12
iPS cells from G551D patients Documents, reports 2019-07-26 14:38:12
iPS cells from F508del patients Documents, reports 2019-07-26 14:38:12
Intestinal organoids from G551D patients Documents, reports 2019-07-26 14:38:12
Calu-3 mutant CFTR F508del and G551D cells Documents, reports 2019-07-26 14:38:13
Intestinal organoids from F508del patients Documents, reports 2019-07-26 14:38:12
pH-insensitive Cl- sensor assay Documents, reports 2019-07-26 14:38:13
Lung epithelial cells from G551D patients Documents, reports 2019-07-26 14:38:13
Correlation of anion transport activity with mucin release in Calu-3 CFTR wt and mutant sensor cell lines Documents, reports 2019-07-26 14:38:12

Take a look to the deliverables list in detail:  detailed list of TAT-CF deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Aarne Fleischer, Iván M. Lorenzo, Esther Palomino, Trond Aasen, Fernando Gómez, Miguel Servera, Víctor J. Asensio, Víctor Gálvez, Juan Carlos Izpisúa-Belmonte, Daniel Bachiller
Generation of two induced pluripotent stem cell (iPSC) lines from p.F508del Cystic Fibrosis patients
published pages: 1-5, ISSN: 1873-5061, DOI: 10.1016/j.scr.2018.03.004
Stem Cell Research 29 2019-07-26
2018 Ángel del Pozo, Roberto Quesada, Manfred Frey
4th TAT-CF Newsletter
published pages: , ISSN: , DOI:
2019-07-26
2018 Ángel del Pozo, Roberto Quesada, Oscar Moran, Emanuela Caci, Manfred Frey, Daniel Bachiller, Anette Mullertz, Laszlo Puskas
6th TAT-CF Newsletter
published pages: , ISSN: , DOI:
2019-07-26
2018 Ángel del Pozo, Roberto Quesada
5th TAT-CF Newsletter
published pages: , ISSN: , DOI:
2019-07-26
2018 Ángel del Pozo, Roberto Quesada, Oscar Moran, Emanuela Caci
3rd TAT-CF Newsletter
published pages: , ISSN: , DOI:
2019-07-26
2018 Elsa Hernando, Valeria Capurro, Claudia Cossu, Michele Fiore, María García-Valverde, Vanessa Soto-Cerrato, Ricardo Pérez-Tomás, Oscar Moran, Olga Zegarra-Moran, Roberto Quesada
Small molecule anionophores promote transmembrane anion permeation matching CFTR activity
published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-018-20708-3
Scientific Reports 8/1 2019-07-26
2018 Claudia Cossu, Michele Fiore, Debora Baroni, Valeria Capurro, Emanuela Caci, Maria Garcia-Valverde, Roberto Quesada, Oscar Moran
Anion-Transport Mechanism of a Triazole-Bearing Derivative of Prodigiosine: A Candidate for Cystic Fibrosis Therapy
published pages: , ISSN: 1663-9812, DOI: 10.3389/fphar.2018.00852
Frontiers in Pharmacology 9 2019-07-26

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TAT-CF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TAT-CF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More